Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Research and Innovation Action · Running

PROMINENT Precision Medicine Platform in Neurodegenerative Disease

Coordinator
Karolinska Institutet, Sweden
Runs
1 May 2023 to 30 April 2028
Status
Running
EU funding
€6.1m
Total cost
€11.1m
Partners
18 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101112145

What the project is doing

In the project's own words, from its summary on CORDIS.

Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Comorbidities with these conditions are frequent and a major obstacle to optimal diagnosis and management. Recent advances in diagnostic technologies and the advent of disease-modifying therapies (DMT) for Alzheimer’s disease (AD), the most common aetiology of dementia, heralds the beginning of precision medicine in this disease area.

PROMINENT will develop a digital platform for precision medicine that will remove barriers that currently exists for leveraging these technological advancements in the routine care of patients with neurodegenerative disorders and co-morbidities. The platform gives clinicians access to prediction models leveraging multimodal diagnostic data automatically derived from multiple sources (imaging repositories, medical records, mobile devices), helping them choose optimal care pathways and improving diagnostic precision.

It will provide personalized, relevant and meaningful information on diagnosis and prognosis in a format understandable by patients and care partners. Further, it will support the introduction of new health technologies such as DMT for AD, by ensuring adherence to appropriate use guidelines and facilitating the prospective collection of data on real-world usage, safety and effectiveness. The expected impact of the project is to increase diagnostic accuracy and optimized use of existing and new treatment options.

It will empower patients and caregivers by engaging them in more person-centric health care decisions, leading to improved adherence and patient experience. Ultimately this is expected to lead to cost-effective care, improved health outcomes and quality of life.

Who is involved

OrganisationCityCountryRole
Karolinska InstitutetStockholmSwedenCoordinator
Deutsches Zentrum Fur Neurodegenerative Erkrankungen eVBonnGermanyParticipant
Klinikum Der Universitaet Zu KoelnKoelnGermanyParticipant
Region HovedstadenHillerodDenmarkParticipant
Fundacio Barcelonabeta Brain Research CenterBarcelonaSpainParticipant
Synapse Research Management Partners SLMadridSpainParticipant
Combinostics OyTampereFinlandParticipant
Ita-Suomen YliopistoKuopioFinlandParticipant
Chu Hopitaux De BordeauxTalenceFranceParticipant
Alzheimer EuropeSenningerbergLuxembourgParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Oslo Universitetssykehus HfOsloNorwayParticipant
Bioarctic ABStockholmSwedenParticipant
Ihe, Institutet for Halso- Och Sjukvardsekonomi AktiebolagLundSwedenParticipant
Region StockholmStockholmSwedenParticipant
Stiftelsen Fingers Brain Health InstituteSolnaSwedenParticipant
Univerzitetni Klinicni Center LjubljanaLjubljanaSloveniaParticipant
Combinostics Us IncBostonUnited StatesThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI